Slides
Page 1
Company Update James McBrayer CEO & Managing Director Jason Smith Chief Financial Officer For personal use only
Page 2
Agenda • 2024 Overview & Financial Results • Third Party Distribution • Technegas Technology • USA Update • Beyond PE • Q&A For personal use only
Page 3
3 Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the markets for the company's products. Such statements, estimates and projections reflect various assumptions made by the directors concerning anticipated results, which assumptions may or may not prove to be correct. Cyclopharm Limited has not sought independent verification of information in this presentation. While the directors believe they have reasonable grounds for each of the statements, estimates and projections and all care has been taken in the preparation, no representation or warranty, express or implied, is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of statements, estimates and projections contained in this presentation. Such statements, estimates and projections are by their nature subject to significant uncertainties, contingencies and assumptions. T o the maximum extent permitted by law, none of the Cyclopharm Limited, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of information contained in this presentation. All references to dollars unless otherwise specified are to Australian dollars. This presentation was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary. SAFE HARBOUR STATEMENT For personal use only
Page 4
2024 Overview For personal use only
Page 5
Technegas was introduced clinically in 1986. New era of Technegas imaging developing driven by AI Technegas generators are available now in 66* countries. Direct distribution in 17 countries Over 5.0 million patient procedures to date Leveraging global infrastructure with Business Partner Product distribution *Czech Republic grants marketing approval for Technegas on 6 August 2024 For personal use only
Page 6
Technegas installed at 17 US sites in 2024 with a further building upon a strong and growing opportunity pipeline. Continued growth in Third-Party distribution sales, including an increase of 57% in the second half, to deliver a 4% increase in revenues on the pcp. Ramp up of US sales of Technegas accelerating, with key opinion leaders emerging as early adopters and revenue up 131% in the second half of 2024 compared to the first half. Successful $20 million Capital Raising followed by over-subscribed $4 million Share Purchase Plan in 2024 underscores shareholder support for Cyclopharm’s growth strategy. 1 2 3 4 5 6 Strong balance sheet with $20.6 million of net cash at 2024-year end to support US growth. 7 Technegas now in 66 countries and a strong second half of 2024 supported record global sales up 5% on the prior corresponding period (pcp). Cyclopharm’s Beyond PE strategy to expand the use of TechnegasTM validated by ongoing clinical trials, including a new French trial into residual pulmonary vascular obstruction. 8 Technegas US growth underpinned by Pass Through reimbursement through in the Center for Medicare and Medicaid Services (CMS) for clinical use. 2025 commenced with significant US sales and supply contracts secured to allow the ease of adoption of Technegas across public and private hospitals.9 For personal use only
Page 7
2024 Full Year Financial Results For personal use only
Page 8
Record Sales Revenue $27.6m up 5% from $26.3m in the pcp Technegas Global sales revenue up 5% from the pcp to $15.2 million, with a strong second half up 14%, driven by initial US sales. 3rd Party Distribution Global revenue up 4% from the pcp to $12.4 million Technegas US 1. Initial US Technegas sales drive 5% increase in group revenue 2. Total US sales of $827k includes 131% growth in 2nd half sales 3. 2nd half driven by early adoption by Key Opinion Leaders Net Loss After Tax $13.2m loss up 181% on $4.7m loss in the PCP, which benefited from $4.5 million of positive adjustments Balance Sheet $20.6 m of cash reserves as @ 31 December 2024 to drive our growth strategies For personal use only
Page 9
9 2024 Trading Highlights Technegas • Underpinned by PAS1 sales delivering 72.6% of revenue compared to 70.7% in the pcp • 55 system sales compared to 58 in the pcp (excluding USA) Third Party Distribution • Capital projects revenue up 83% in the 2nd half but overall was down 35% on the pcp • Consumables and service revenue was up 26% overall, including a strong 2 nd half, up 54% on the pcp Regulatory Renewals All regulatory renewals in existing 66 country markets maintained Indication Expansion Existing ‘Beyond PE’ clinical trials progressing. French trial use of Technegas to improve detection of residual pulmonary vascular obstruction initiated Group Revenue Trend by Category (last 3 years) 1 Patient Administration Set (PAS) box equals 50 patient Technegas procedures. $0m $5m $10m $15m $20m $25m $30m 2022 2023 2024 Third-Party Equipment Third-Party Consumables & Service Technegas For personal use only
Page 10
Third-Party Products Overview For personal use only
Page 11
Third-Party Products comprise the following components Consumables and Radiopharmaceuticals Hotcells for Radiopharmaceutical Manufacturing Patient Injectors Equipment Sales Pharmaceutical Delivery systems Radiation Monitors SUPPORT Training Engineering Support & Service Regulatory Registration Direct sales and Service in 17 out of 66 approved markets Equipment sales – tender / project driven (non-linear) Razor - Razorblade Model business model with consumables linked to equipment sales Pharmaceutical wholesale licenses required Leveraging our Sales, Service & Regulatory Footprint in our Direct Markets For personal use only
Page 12
Technegas Overview For personal use only
Page 13
Technegas unlocking the clinical potential of lung imaging by leveraging state of the art techniques (SPECT, SPECT/CT & analytical software with AI) 1,2. Technegas is the nuclear medicine functional ventilation imaging agent of choice - Technegas shows true functional ventilation with operational and clinical advantages over competitive agents4. 1 2 3 4 Nuclear Medicine delivers superior clinical outcomes in diagnosing PE at exponentially lower radiation dose than CTPA3. Nuclear medicine with Technegas paired with AI and analytical software, is unlocking a new era in lung imaging. 1. Hess S, et al. Semin Thromb Hemost 2016; 42(8): 833-845 2. Reinartz P, et al. J Nucl Med 2004; 45: 1501-1508 3. Leblanc M, et al. CANM guidelines; Nov 2018: www.canm-acmn.ca/guidelines 4. Le Pennec, et. al. Clinical Nuclear Medicine 49(11):p 997-1003, November 2024. | DOI: 10.1097/RLU.0000000000005396 Leveraging Analytical Sof For personal use only
Page 14
14 Functional Imaging showing where Oxygen is distributed within the lung Technegas is composed of 99mTc cores encapsulated within layers of graphite to form individual hexagonal plate-like particles.1-2 Technegas is manufactured by heating Technetium-99m in a carbon crucible within an argon environment for a few seconds at 2,750 degrees Celsius. 3 Its very small particle size (>80 less than 1 micron or 1,000 nm 4) allows distribution into the lungs like a gas and deposited in alveoli by diffusion, providing for Planar, SPECT and SPECT/CT ventilation imaging. 1. Wiebe LI, et al. Current Radiopharmaceuticals 2010; 3(1): 49-59 2. Blanc-Béguin F, et al. Mol Imaging Biol 2020; 3. Lemb M, et al. Eur J Nucl Med 1993; 20(576-579) 4. Pharmaceutics 2023, 15(4), 1108; https://doi.org/10.3390/pharmaceutics15041108 Image source: Blanc-Béguin et al, 2020 How big is a nanometre? o 100,000 nm = Sheet of paper thickness o 75,000 nm = Human hair thickness o 7,000 nm = Red Blood Cell diameter o 2.5 nm = DNA strand diameter For personal use only
Page 15
Unique Drug + Device + Service combination = regulatory barrier to entry T echnegas comprises the following components SYSTEM TECHNEGAS PLUS SYSTEM Technegas (Crucible) Technegas® Contacts PER PATIENT CONSUMABLES TECHNEGAS ® SYSTEM PACK Technegas Patient Administration Set (PAS) IN ADDITION TO THE SYSTEM PACK Nose Clips SUPPORT Training Engineering Support & Service Image Analysis USFDA Drug-Device Combination product Razor - Razorblade Model business model Per-patient consumables drive an annuity-like revenue stream All Technegas components are manufactured / assembled by Cyclopharm For personal use only
Page 16
Hierarchy of Evidence 16 Technegas has A High Standard of Clinical Evidence to Drive Adoption in Traditional & Beyond PE Applications For personal use only
Page 17
17 Technegas - the ventilation imaging agent of choice in established markets 85% of nuclear medicine ventilation studies ex-USA are performed using Technegas Xenon-133 has been displaced in all markets where Technegas is available SPECT imaging used in >95% outside the USA vs 32% in the USA Beyond PE applications gaining traction in CTEPH, Interventional Respiratory medicine, radiation therapy planning, lung transplant & PE follow-up Some USA nuclear medicine departments have not resumed ventilation imaging since COVID Survey conducted before T echnegas USA launch highlights that: • “The most striking result of this survey is the discrepancy in practices in the United States compared with other countries…… • ”The different physical physiological properties of ventilation agents may explain the differences in the choice of acquisition protocols (in the USA)…… • “The recent FDA approval of 99mTc-Technegas may change practices…..” For personal use only
Page 18
Technegas USA Expansion For personal use only
Page 19
------------------USFDA APPROVED INDICATIONS AND USAGE------------------- TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older for: • visualization of pulmonary ventilation • evaluation of pulmonary embolism when paired with perfusion imaging 19 Technegas (kit for the preparation of technetium Tc99m labeled carbon inhalation aerosol) for oral inhalation use – NDA 022335 Potential applications across the entire field of respiratory medicine For personal use only
Page 20
20 * Revenue and patient volume projections based on internal company analysis **Leblanc M, et al. CANM 2018; https://canm-acmn.ca/resources/Documents/Guidelines_Resources/MasterDocument_Final_Nov_21_incl-Exec-Sum_ver3_Dec.%2012_.pdf 2.a 85%/3.4M 15%/600k IMMEDIATE PULMONARY EMBOLISM MARKET OPPORTUNITY Nuclear Medicine CTPA 600K Nuclear Medicine Ventilation Procedures p.a. in the USA* for PE Estimated 4,000,000 pulmonary embolism procedures in the USA p/a (15% Nuclear Medicine / 85% CTPA) ~600,000 (15%) Nuclear Medicine procedures represents an initial US$90m addressable market Initial target for Technegas® ~480,000 patient procedures Technegas expected to displace Xe133 followed by DTPA as the standard of care nuclear medicine diagnostic product in the US 3D SPECT imaging using Technegas is proven to be clinically superior and safer than CTPA** Cyclopharm’s target is to double the existing nuclear medicine PE market in the US, which is dominated by CTPA, from 15% to 30% increasing the addressable market for PE to US$180m US entry expected to drive our Beyond PE strategy leveraging AI to use Technegas for additional disease states (asthma, long-Covid etc.) which are exponentially larger than the existing markets 1 2 3 4 5 6 7 For personal use only
Page 21
21 Establishing a Network of Key Opinion Leader (KOL) Locations 24 US installations to date $ 1.37m generated in sales since approval - US Revenue 2025 is $543k CMS Pass Through reimbursement Strong pipeline – expanding installation within existing customer buying groups and leveraging off regional KOL’s Contracts secured in January & March 2025 with the largest Government and Private Healthcare Groups in the USA Rollout Update as of 18 March 2025: For personal use only
Page 22
Understanding the US Opportunity For personal use only
Page 23
23 Placement Model to Expedite Consumable Demand US$7k one-off installation and training fee US$7k p.a. technology fee, includes servicing Annuity Revenue Per patient fee for consumables (sold in 50 patient units) US$70k revenue per system per annum expected from larger sites1 >15 yrs average life per system Targeting 2,000 of the 8,000 US nuclear medicine departments. 250-300 total installations achieved during the second half 2026. System Placement model supports rapid uptake by US customers by removing the initial capital outlay to drive implementation of the technology Initial focus on clinical trial and high-volume sites for the greatest clinical impact and greater repeat demand for consumables Modest cost base for US roll-out - ~US$6.5m operating costs per annum in 2025 High consumable annuity gross margins expected at greater than 80% $180m USD market for diagnosing PE. Beyond PE applications to significantly grow the global market 1. Calculation based on expected demand and market price for competing products (e.g. Xe133). For personal use only
Page 24
24 Pulmonary Embolism: Timeline USA PE Market Share Market size Horizon 1 – Full displacement of existing nuclear medicine tests for PE 0 - 5 years 15% US$90m Horizon 2 – Commence converting CTPA exams to Technegas 0 - 8 years 30% US$180m* Beyond Pulmonary Embolism: Timeline Global Market size Horizon 3 – Expanding Beyond PE Globally into new indications such as asthma and chronic obstructive pulmonary disease > 8 years US$900m Total long term revenue opportunity >US$1.1bn *Assumes Combined Nuclear Medicine and CTPA Market Exponential Growth Opportunity Over The Next Decade 1 2 3 For personal use only
Page 25
Beyond PE: Blue Sky For personal use only
Page 26
26 1. Roach PJ, et al. J Nucl Med 2013; 54: 1588-1596 2. Ohira H, et al. J Nucl Cardiol 2015;22(1): 141-157 3. Hsu K, et al. J Bronchology Interv Pulmonol 2018; 25(1): 48-53 4. Mortensen J, Berg RMG. Semin Nucl Med 2019; 49(1): 16-21 5. Wechalekar K, et al. Semin Nucl Med 2019; 49(1): 22-30 6. Elojeimy S, et al. AJR Am J Roentgenol 2016; 207(6): 1307- 1315 7. Eslick EM, et al. Semin Nucl Med 2019; 49(1): 31-36 8. Farrow C, King GG. Semin Nucl Med 2019; 49(1): 11-15 9. Jögi J, et al. Int J Chron Obstruct Pulmon Dis 2014; 10: 25-30 10. Bajc M, et al.. Int J Chron Obstruct Pulm Dis 2017; 12: 1579- 1587 11. Verger A, et al. Eur J Nucl Med Mol Imaging 2020; 47(11): 2709-2710 12. Baloul A, et el, Eur J Nuc Med Mol Imaging 2021; 48(8):2525- 2530 13. Bajc M, et al, Clin Med Insights 2021; Vol 14 1-4 14. Blanc-Beguin F, et al, Mol Img Bio 2021, 23:62-69 15. Currie G, J Nuc Med Tech 2021; 49:313-319 16. Ozguven, S, et al; Mol Imag Rad Therapy; 2021: 30:28-33 17. Tee, et al; Intrevent Pulmonology; 2021, DOI 10.1159/000515336 18. Le Roux, et al, J Nuc Med July 2022, 63 (7) 1070-1074 19. Berhouse, et al, Respiratory Research 2022; 23: 296 20. Ridiadia, et al, ATS Abstract; doi.org/10.1164/ajrccm- conference.2022.205.1_MeetingAbstracts.A2554 21. Venegas C, et al, ATS Abstract; doi.org/10.1164/ajrccm- conference.2022.205.1 22. Le Roux, et al; Clinical Nuclear Medicine, 27 Oct 2022; doi: 10.1097/RLU.0000000000004426 *Including PE applications. On a long-term basis. See Slide 26 ‘Horizon 3 for further details. Clinical trials already underway For personal use only
Page 27
27 1. ACTRN12617001275358 - Can functional lung ventilation imaging identify treatable traits in obstructive airway disease? 2. https://clinicaltrials.gov/ct2/show/NCT04191174?term=technegas&draw=2&rank=3 3. http://investor.cyclopharm.com/site/PDF/1561_0/BetterDefiningAirwaysDiseasewithTechnegas 4. https://ichgcp.net/clinical-trials-registry/NCT03728712 5. https://clinicaltrials.gov/ct2/show/NCT04549636 6. https://pubmed.ncbi.nlm.nih.gov/38151119/ 7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206636/ 8. https://classic.clinicaltrials.gov/ct2/show/NCT06372730 PATIENT MANAGEMENT & SCREENING Response to Therapy and Personalized Medicine INTERVENTIONAL THERAPIES LVRS, ELVR, Transplant, Lung Cancer CHRONIC AIRWAY DISEASES COPD – Asthma PULMONARY EMBOLISM (PE) VTE – CTEPH - PH 7 Cyclopharm sponsored Beyond PE clinical trials – US approval expected to drive clinician led studies Hunter Medical Research Institute (Newcastle, AU): Diagnosis and response to therapy in severe asthma and COPD1 - 100 Patient Study * 100% Recruited * Study Published6, Woolcock Institute (Sydney, AU): Diagnosis and response therapy in mild to moderate COPD3 44 Patient* 100% Completed CHUM (Montreal, CA): Early detection of COPD in asymptomatic smokers4 30 Patient Study * 100% Recruited * Analysis complete * Paper submitted for publication Dalhousie (Halifax, CA): Post-lung transplant patients - 30 Patient Study * 30% Recruited McMaster University Firestone Institute (Hamilton, CA): Ventilation in lung cancer patients pre and post lung resection 2; 100% Recruited * Study Published bridging research initiatives with clinical applications using Technegas . McMaster University Firestone Institute (Hamilton, CA): COVID-19 Related Lung Ventilation and Perfusion Injury5 100% Recruited * Abstract presented at the American Thoracic Society May 2023 with paper to follow. PRONOSPECT (France): 665 Patient multicentre trial designed to Predict the Risk of Venous Thromboembolism (VTE) Recurrence in Patients With Pulmonary Embolism (PE). Patients will be imaged with nuclear medicine regardless if initially diagnosed with CTPA or nuclear medicine8. Recruitment commenced. 4 1 2 3 5 6 7 For personal use only
Page 28
Cyclopharm Investment Case For personal use only
Page 29
29 Profitable and Growing MedTech Underlying business (ex- USA) is cash positive First in Class Established Gold Standard Proprietary product sales to 66 countries with over 5 million patient procedures to date Clinical Agent of Choice referenced by name in multiple nuclear medicine clinical guidelines Technegas IP Expansion Program Underway Recurring Revenue From single patient consumables Similar to an annuity model Generating Recurring Revenues from all USA installations USFDA Approval Granted Set to quadruple the size of the existing PE business, based on significant existing demand Further leverage penetration into the CTPA market Full Reimbursement Granted from 1 July 2024 Technegas Product expansion Indications Beyond PE leveraging AI into chronic respiratory disease management in large uses such as asthma, COPD and lung cancer could deliver exponential growth Market Development already underway Outlook: 250 - 300 Technegas USA Installations achieved during Second Half 2026 For personal use only
Page 30
Questions For personal use only
Page 31
Attachment Section For personal use only
Page 32
32 SNMMI Technegas Press Release – USA Catching up with the R.O.W. September 29, 2023 Reston, VA—The U.S. Food and Drug Administration (FDA) has approved the imaging agent Technegas for use in ventilation–perfusion studies to diagnose pulmonary embolism and other respiratory pathologies. A carbon-based nanoparticle developed in Australia nearly 40 years ago, Technegas has been recognized as a standard for ventilation studies and is widely used in clinics around the world. Benefits of Technegas include high diagnostic accuracy, low radiation burden to patients, and easy administration. It offers advantages for scanning of COVID-19 patients, as the procedure is quick and the apparatus is single use, without recirculation. In 2021, SNMMI urged FDA to begin a fast-track review of the agent. “We applaud the FDA for the long-awaited approval of Technegas,” said SNMMI president Helen Nadel, MD, FRCPC, FSNMMI. “Technegas will offer advantages in diagnostic accuracy, workflow, and patient comfort for departments that adopt the technology and will have a large impact on those undergoing imaging for pulmonary disease.” Pulmonary embolism affects approximately 900,000 Americans per year, and more than 34 million Americans live with chronic lung disease, according to the American Lung Association. Technegas is manufactured by Cyclomedica and is currently distributed to 54 countries worldwide. https://snmmi.org/Web/News/Articles/FDA-Approves-Widely-Used-Imaging-Agent-for- Respiratory-Disease “Recognised standard for ventilation studies” FDA Approves Widely Used Imaging Agent for Respiratory Disease “Diagnostic Accuracy” “Improved workflow” “Patient Comfort” “Large impact on those undergoing imaging for pulmonary disease” For personal use only
Page 33
33 Endorsed by the guidelines from the European1-2 and the Canadian3 Associations of Nuclear Medicine (EANM & CANM) 1. Bajc M, et al. Eur J Nucl Med Mol Imaging 2019; [Epub ahead of print]: https://link.springer.com/content/pdf/10.1007%2Fs00259-019-04450-0.pdf 2. Bajc M, et al. Eur J Nucl Med Mol Imaging 2009; 36(8): 1356-70; https://eanm.org/publications/guidelines/gl_pulm_embolism_part1.pdf 3. Leblanc M, et al. CANM 2018; https://canm-acmn.ca/resources/Documents/Guidelines_Resources/MasterDocument_Final_Nov_21_incl-Exec-Sum_ver3_Dec.%2012_.pdf 2.a “ Using 99m-Tc-Technegas® is according to clinical experience better than the best aerosols ” “ Technegas® facilitates interpretation, particularly in COPD” “ For ventilation, 99m-Tc Technegas® is the best-aerosol particularly in patients with COPD ” “ Liquid aerosols are inferior for SPECT and should not be used unless Technegas® is not available ” “ The best widely available agent for ventilation is 99m-Tc-Technegas ” “ Because of the very small particle size, this agent is distributed in the lungs almost like a gas and deposited in alveoli by diffusion, where they remain stable, thus providing the best possible images for ventilation SPECT ” “ Another advantage is that only a few breaths are sufficient to achieve an adequate amount of activity in the lungs, reducing time and personnel exposure to radiation ” “ Technegas® is considered the agent of choice in the COPD population as there is less central airway deposition, better peripheral penetration, and it does not wash out as quickly as traditional aerosols ” Technegas is the nuclear medicine agent of choice in established markets For personal use only
Page 34
34 Recent Research and Articles Driven by Clinicians and End Users: Technegas -Technegas at Last! Implementing Technegas into Clinical Practice in the United States: Considerations, Challenges, and Recommendations Delynn Silvestros and Tina M. Buehner; Journal of Nuclear Medicine Technology March 2025, 53 (1) 7-10; DOI: https://doi.org/10.2967/jnmt.124.269231 Comparability of Quantifying Relative Lung Ventilation with Inhaled 99mTc- Technegas and 133Xe in Patients Undergoing Evaluation for Lung Transplantation Ashwin Singh Parihar, Joyce C. Mhlanga, Henry D. Royal and Barry A. Siegel Journal of Nuclear Medicine December 2024, jnumed.124.268801; DOI: https://doi.org/10.2967/jnumed.124.268801 Ventilation Lung Imaging: Technegas Mary Beth Farrell, Kathy S. Thomas, Eleanor S. Mantel and Jessica Settle; Journal of Nuclear Medicine Technology February 2025, jnmt.125.269536; DOI: https://doi.org/10.2967/jnmt.125.269536 For personal use only
Page 35
Peer Reviewed clinical studies have shown that V/Q SPECT/CT is superior compared to CTPA across most clinical measures with better overall diagnostic performance1. 0% 25% 50% 75% 100% Sensitivity Specificity PPV NPV Accuracy V/Q SPECT/CT V/Q SPECT CTPA V/Q Planar Diagnostic ability of V/Q SPECT/CT1, V/Q SPECT1, CTPA1 and V/Q Planar2 to detect PE (adapted from Hess and al, 20161 and from Reinartz et al, 20042) 1. Hess S, et al. Semin Thromb Hemost 2016; 42(8): 833-845 2. Reinartz P, et al. J Nucl Med 2004; 45: 1501-1508 3. Leblanc M, et al. CANM guidelines; Nov 2018: www.canm- acmn.ca/guidelines 35 Nuclear Medicine VQ radiation dose, even combined with low dose non- contrast CT, is exponentially lower than CTPA 1 3.1 20 VQ SPECT or Planar VQ SPECT/ CT CTPA Radiation Dose mSv Nuclear Medicine vs CTPA For personal use only
Page 36
36 The Canadian Case Study - a strong indicator of USA acceptance Canada is Cyclopharm’s largest single country market to date Technegas® is market leader for diagnosing PE and is nearing 100% nuclear medicine market share Xe-133 rapidly displaced by early adopters Close correlation with the number of active generators and annual consumable sales Market launch initiated province by province, leveraging off pilot sites Patient volumes continue to recover post COVID (to include temporary gains in 2022 from the global CT contrast media shortage) with further conversion of additional lower volume sites in 2023 1 2 3 4 5 6 For personal use only
Page 37
37 Easy 3 to 4 breaths 3D images Te c h n e g a s® Xenon - 133 True radioactive gas inhaled with full face mask Constant inhale -exhale breathing for 15 mins increasing the risk of COVID-19 exposure No 3D images limited to planar imaging resulting in lower sensitivity & specificity Requires special rooms to contain radioactive gas in the event of a release DTPA T c99m Wet Aerosol impacts efficacy, bronchospasm, COVID-19 concerns Creates hotspots in presence of small airways lung diseases, a frequent comorbidity in PE, & impacts clinical interpretations No contraindications Covid-19 For personal use only
Page 38
The importance, urgency and opportunity ‘Beyond PE” underway 1 2 Lung Disease in 2019 accounted for 6 million deaths worldwide (12% of all deaths) COPD and Lower Respiratory Infections and Lung Cancer will be the 3rd, 4th and 6th largest causes of death by 2030. “Over and underdiagnosis of Lung Disease has a huge economic impact. COPD misdiagnosis revealed that the under or over diagnosis and prevalence of this disease was 56.7–81.4% and 29.0–65.0%, respectively leading to 55.4% squandering of treatment costs 2” 3 4 Misdiagnosis can be fatal 1. World Health Organisation - The top 10 causes of death 2019 (who.int) 2. Munir, M., Setiawan, H., Awaludin, R. et al. Aerosolised micro and nanoparticle: formulation and delivery method for lung imaging. Clin Transl Imaging (2022). https://doi.org/10.1007/s40336-022-00527-3 5 Exponential Growth Potential for T echnegas For personal use only